Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Background This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials.